Boceprevir a valuable addition for hepatitis C

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.643, 2011-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus

By Shankar Hari Bichoupan Kian Dieterich Douglas T

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 12, 2013-12 ,pp. : 1647-1657

Informa Healthcare

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite

Boceprevir a cost-effective addition in HCV therapy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 671, 2013-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Boceprevir

Drugs in R&D, Vol. 10, Iss. 3, 2010-09 ,pp. : 203-210

Adis International

Access to resources Recommend Favorite

Addition of ketoprofen to IFN- -2b beneficial in hepatitis C?

Inpharma, Vol. 1, Iss. 1231, 2000-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite